The decision to use a combination as initial therapy should be individualized and should beu00a0shaped by considerations such as baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared to monotherapy. Patients with moderate or severe hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant.Azoru00a0may also be used as initial therapy in patients who are likely to need multiple antihypertensive agents to achieve their blood pressure goals.These considerations may guide selection of therapy. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease).Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, sou00a0the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit.The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits.For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Programu2019s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Many patients will require more than one drug to achieve blood pressure goals. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake.There are no controlled trials demonstrating risk reduction with Azor. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarctions. Azor is indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure."PHARMACOKINETICS - Pharmacokinetics of Amlodipine and Olmesartan After Administration of Amlodipine Besylate and Olmesartan Medoxomil in Separate Dosage Forms and as a Fixed-Dose Combination". Shashank Rohatagi, James Lee, Magdy Shenouda, MD, Stephen Haworth, MD, Mohinder Singh Bathala, Mark Allison, MD, Igor Rubets, Reinilde Heyrman, MD, Robert Noveck, MD and Daniel E.Archived from the original on 29 September 2009.
"Information about Azor from the manufacturer".
"The AZTEC Trial: Amlodipine Besylate/Olmesartan Medoxomil (Azor)".
0 kommentar(er)
